BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Rating) CEO Jean Jacques Bienaime sold 20,000 shares of the business’s stock in a transaction on Monday, April 18th. The shares were sold at an average price of $81.91, for a total transaction of $1,638,200.00. Following the completion of the transaction, the chief executive officer now owns 334,983 shares in the company, valued at approximately $27,438,457.53. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Jean Jacques Bienaime also recently made the following trade(s):
- On Thursday, April 14th, Jean Jacques Bienaime sold 10,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $83.66, for a total transaction of $836,600.00.
- On Thursday, March 10th, Jean Jacques Bienaime sold 15,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $77.57, for a total value of $1,163,550.00.
Shares of NASDAQ BMRN traded up $0.03 during mid-day trading on Wednesday, reaching $80.61. 1,238,637 shares of the company’s stock were exchanged, compared to its average volume of 1,304,187. The firm has a 50-day moving average price of $81.20 and a two-hundred day moving average price of $83.16. The company has a debt-to-equity ratio of 0.25, a current ratio of 4.21 and a quick ratio of 2.77. The firm has a market capitalization of $14.90 billion, a price-to-earnings ratio of -223.92, a price-to-earnings-growth ratio of 1.83 and a beta of 0.49. BioMarin Pharmaceutical Inc. has a 52 week low of $71.59 and a 52 week high of $94.20.
A number of equities analysts recently issued reports on the company. StockNews.com assumed coverage on BioMarin Pharmaceutical in a report on Thursday, March 31st. They issued a “hold” rating on the stock. Morgan Stanley raised their price objective on shares of BioMarin Pharmaceutical from $90.00 to $96.00 and gave the company an “equal weight” rating in a research note on Tuesday, April 12th. Truist Financial boosted their target price on shares of BioMarin Pharmaceutical from $125.00 to $135.00 in a research report on Monday, January 10th. Piper Sandler raised their price target on shares of BioMarin Pharmaceutical from $121.00 to $125.00 and gave the company an “overweight” rating in a research report on Thursday, February 24th. Finally, Wedbush reiterated an “outperform” rating and set a $155.00 price target on shares of BioMarin Pharmaceutical in a report on Thursday, February 24th. Five equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $112.14.
Several large investors have recently bought and sold shares of the stock. Kestra Advisory Services LLC grew its holdings in BioMarin Pharmaceutical by 8.2% during the third quarter. Kestra Advisory Services LLC now owns 3,971 shares of the biotechnology company’s stock valued at $307,000 after purchasing an additional 300 shares during the period. Janney Montgomery Scott LLC lifted its position in shares of BioMarin Pharmaceutical by 4.8% during the 3rd quarter. Janney Montgomery Scott LLC now owns 35,793 shares of the biotechnology company’s stock valued at $2,766,000 after buying an additional 1,641 shares during the last quarter. Landsberg Bennett & Dubbaneh LLC bought a new position in shares of BioMarin Pharmaceutical during the 3rd quarter worth $408,000. Nordea Investment Management AB increased its holdings in BioMarin Pharmaceutical by 100.0% in the 3rd quarter. Nordea Investment Management AB now owns 17,256 shares of the biotechnology company’s stock worth $1,332,000 after acquiring an additional 8,628 shares during the last quarter. Finally, B. Metzler seel. Sohn & Co. Holding AG raised its stake in BioMarin Pharmaceutical by 28.7% in the 3rd quarter. B. Metzler seel. Sohn & Co. Holding AG now owns 11,562 shares of the biotechnology company’s stock valued at $894,000 after acquiring an additional 2,581 shares during the period. 91.71% of the stock is currently owned by institutional investors.
BioMarin Pharmaceutical Company Profile (Get Rating)
BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
- Get a free copy of the StockNews.com research report on BioMarin Pharmaceutical (BMRN)
- Highly Valued Abbot Laboratories Could Move Lower
- Baker Hughes, Another Buy-The-Dip Opportunity In Oilfield Services
- Netflix (NASDAQ: NFLX) Falls Back to 2018 Levels
- Is Turning Point Therapeutics Stock at a Turning Point?
- Buy Haliburton On Post-Earnings Weakness
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.